InvestorsObserver
×
News Home

Will AcelRx Pharmaceuticals Inc (ACRX) Stay at the Top of the Healthcare Sector?

Thursday, January 12, 2023 01:48 PM | InvestorsObserver Analysts

Mentioned in this article

Will AcelRx Pharmaceuticals Inc (ACRX) Stay at the Top of the Healthcare Sector?

AcelRx Pharmaceuticals Inc (ACRX) is near the top in its sector according to InvestorsObserver. ACRX gets an overall rating of 25. That means it scores higher than 25% of stocks. AcelRx Pharmaceuticals Inc gets a 72 rank in the Healthcare sector. Healthcare is number 3 out of 11 sectors.

Overall Score - 25
ACRX has an Overall Score of 25. Find out what this means to you and get the rest of the rankings on ACRX!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. *Investors Observer* makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With AcelRx Pharmaceuticals Inc Stock Today?

AcelRx Pharmaceuticals Inc (ACRX) stock is trading at $2.44 as of 1:39 PM on Thursday, Jan 12, an increase of $0.17, or 7.49% from the previous closing price of $2.27. The stock has traded between $2.24 and $2.55 so far today. Volume today is 143,098 compared to average volume of 164,183. Click Here to get the full Stock Report for AcelRx Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App